Compare Amgen, Inc. (AMGN) vs BHP Billiton Limited (BHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs BHP Billiton Limited — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while BHP Billiton Limited trades at $82.08 (market cap $204.10B). The key difference: Amgen, Inc. and BHP Billiton Limited are close in size by market cap, and BHP Billiton Limited pays the higher dividend (3.26%). Which is the better fit depends on your goals.
| AMGN | BHP | |
|---|---|---|
Market Cap | $196.12B | $204.10B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $93.15 |
52-Week Low | $271.18 | $50.37 |
Enterprise Value | $241.41B | $218.31B |
Dividend Yield | 2.77% | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BHP trades at $81.68, up 2.21% today, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $2.24, missing the $2.41 estimate, but beat in Q2 2025. Recent news highlights a potential strike at Port Hedland threatening daily revenue and a $2.3 billion writedown at the Jansen potash project due to cost overruns. Revenue for 2024 was $55.66 billion with a net income margin of 18.97%, while the P/E ratio stands at 20.29.
The outlook is mixed; strong profitability and cash flow support value, but operational disruptions and project cost increases pose near-term risks. Analyst consensus is cautious with 64.52% hold ratings. Investors should weigh solid fundamentals against execution challenges and commodity price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →
